CVS Caremark settles FTC litigation, ends investigations into PBM practices
CVS•Key commitments under the agreement
Settlement commitments include shifting standard commercial offerings away from spread pricing, expanding pricing and rebate reporting, and delinking manufacturer compensation from list prices.
CVS Caremark also agreed to align member cost sharing more closely with net drug costs, add an insulin cap of $25 per month, and adjust reimbursement for independent pharmacies.
Implementation starts under FTC timelines, removing the need for continued litigation and investigations.
FTC settlement resolves PBM litigation and investigations
CVS Health reached a global settlement with the FTC, resolving all outstanding litigation and investigations tied to its PBM and affiliated pharmacy operations.
The FTC matters covered rebate practices, pharmacy network contracting, vertical integration, pricing transparency, and affordability.
